Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE009 (AUS) (Dr. Novak)
· consented 2023-01-17
Adverse events
6
Serious AEs
0
Open data queries
0
Luna dropout signal
–
Adverse events
moderate
assessed
2026-08-18
Grade 2 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2023-02-01 (study day 8); relationship: not assessed
mild
assessed
2026-08-18
Grade 1 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2023-03-03 (study day 38); relationship: not assessed
mild
assessed
2026-08-18
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-03-22 (study day 57); relationship: N
mild
assessed
2026-08-18
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-04-02 (study day 68); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Constipation — outcome: RECOVERED/RESOLVED; onset 2023-04-19 (study day 85); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-06-13 (study day 140); relationship: not assessed
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.